183
Participants
Start Date
August 1, 2016
Primary Completion Date
March 10, 2023
Study Completion Date
December 18, 2024
gilteritinib
Tablet, oral
azacitidine
Subcutaneous injection or intravenous infusion
Site TW88602, Tainan City
Site TW88609, Tainan City
Site BE32007, Brussels
Site BE32003, Brussels
Site AU61004, Liverpool
Site AU61007, Geelong
Site ES34009, Barcelona
Site BE32006, Ghent
Site TW88601, Taipei
Site ES34002, Cáceres
Memorial Sloan-Kettering Cancer Center, New York
Weill Cornell Medical College-New York Presbyterian Hospital, New York
Site TW88608, Taipei
Site TW88610, Taipei
Site DE49003, Berlin
Roswell Park Cancer Institute, Buffalo
Site DE49015, Rostock
Site IT39004, Milan
GHS Cancer Institute, Greenville
Site FR33003, Nîmes
Site DE49004, Hanover
Site ES34003, Oviedo
Site FR33002, Pessac
Site FR33019, Montpellier
Site FR33018, Rennes
Site DE49012, Braunschweig
Site IT39015, Bologna
Site FR33001, Nantes
Site ES34005, Valencia
Site FR33009, Angers
Site KR82014, Busan
Site FR33004, Lille
Site FR33006, Lille
Site FR33023, Valenciennes
Site IT39009, Ancona
Site DE49005, Frankfurt am Main
Rush University Medical Center, Chicago
St. Louis University Cancer Center - Hematology/Oncology, St Louis
Site FR33013, Pierre-Bénite
Site DE49011, Stuttgart
Site IT39011, San Giovanni Rotondo
Site FR33017, Le Mans
Site DE49002, Tübingen
Site FR33015, Rouen
Site IT39001, Napoli
Site DE49007, München
Site TW88604, Kaohsiung City
LDS Hospital, Salt Lake City
Site FR33012, Poitiers
UCLA David Geffen School of Medicine, Los Angeles
Site IT39006, Palermo
University of California, Irvine Medical Center, Orange
Robert H. Lurie Comprehensive Cancer Center, Chicago
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack
Hematology-Oncology Associates of Northern NJ, Morristown
Site AU61008, Adelaide
Site CA15009, Edmonton
Site CA15011, Toronto
Site CA15002, Toronto
Site CA15006, Montreal
Site FR33020, Bayonne
Site IT39012, Florence
Site IT39007, Monza
Site IT39014, Novara
Site IT39005, Pavia
Site JP81018, Anjo
Site JP81007, Nagoya
Site JP81027, Matsuyama
Site JP81021, Fukuyama
Site JP81031, Sapporo
Site JP81033, Sapporo
Site JP81015, Kobe
Site JP81034, Hitachi
Site JP81023, Kanazawa
Site JP81001, Isehara
Site JP81032, Yokohama
Site JP81012, Sendai
Site JP81011, Kurashiki
Site JP81029, Shibuya-ku
Site JP81014, Shinagawa-ku
Site JP81035, Chiba
Site JP81008, Fukuoka
Site JP81024, Gifu
Site JP81005, Kumamoto
Site JP81016, Kyoto
Site JP81004, Nagasaki
Site JP81017, Nagasaki
Site JP81030, Osaka
Site JP81036, Osaka
Site JP81026, Tokushima
Site JP81019, Toyama
Site KR82010, Hwasun-gun
Site KR82015, Seongnam-si
Site ES34013, Madrid
Site TW88605, Kwei Shan Hsiang
Site DE49009, Halle
Site PL48003, Lublin
Site PL48004, Warsaw
Site PL48002, Opole
Site PL48001, Olsztyn
Site KR82003, Namdong
Site KR82013, Seoul
Site KR82006, Seoul
Site KR82002, Seoul
Site KR82001, Ulsan
Site KR82012, Seoul
Site ES34007, Palma de Mallorca
Site ES34008, Barcelona
Site ES34004, Barcelona
Site ES34010, Barcelona
Site GB44007, Sheffield
Astellas Pharma Global Development, Inc.
INDUSTRY